3 terminated, 1 completed, 1 no longer available. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 3 |
| Phase 2 | 1 | Completed 1 |
Follow Palladio Biosciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303 Lixivaptan - Polycystic Kidney Disease, Adult | Phase 3 | Terminated | Palladio Biosciences | 1 | 2022-02-10 | 2023-05-12 |
| Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease Lixivaptan, Placebo - Autosomal Dominant Polycystic Kidney, ADPKD | Phase 3 | Terminated | Palladio Biosciences | 12 | 2021-10-28 | 2023-02-06 |
| Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Lixivaptan - Polycystic Kidney Disease, Adult, ADPKD | Phase 3 | Terminated | Palladio Biosciences | 7 | 2020-09-02 | 2023-04-10 |
| The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Lixivaptan - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Completed | Palladio Biosciences | 31 | 2018-09-14 | 2022-12-05 |
| Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease Lixivaptan - Polycystic Kidney | No longer available | Palladio Biosciences | 2021-10-14 |
Polycystic Kidney, Autosomal Dominant (4) · Polycystic Kidney Diseases (1)
lixivaptan (5)
United States (5) · Australia (1) · Bulgaria (1) · Hungary (1) · Poland (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Arlene Chapman, MD (1) · Marie C Hogan, MD, PhD (1) · Nelson Kopyt, DO (1) · Vicente E Torres, MD, PhD (1) · Vicente Torres, MD, PhD (1)